SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly
LLY 1,058+3.7%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (64)1/29/1998 5:02:00 PM
From: Frank Stein  Read Replies (1) of 643
 
PFIZER INC. Interim Clinical Trial Results Show Droloxifene Offers "No Benefit Beyond the Current
Therapy" at Dose Studied

Jan. 22, 1998, Pfizer Inc. (NYSE:PFE - news) stated that interim results from the worldwide clinicial trial of droloxifene for
the treatment of advanced estrogen-receptor-positive breast cancer have shown that, at the dose studied, ''droloxifene offers
no benefit beyond the current therapy.'' PFE said it will not submit the droloxifene New Drug Application for treatment of
breast cancer in the fourth quarter of 1998 as originally anticipated.

PFE said it is shifting the focus of its developmental program for droloxifene from treatment of advanced breast cancer to
prevention of osteoporsis. The company also said that it plans to investigate the use of droloxifene in the prevention of breast
cancer and other potential health issues of post-menopausal women.

In addition, PFE stated that exploration of the anti-arthritic agent, tenidap, for possible future development as a
disease-modifying agent for osteoarthritis, has now been discontinued. PFE note that future research will focus on back-up
anti-arthritis compounds with potentially enhanced safety and efficacy characteristics.

The company also said it will file an New Drug Application with the FDA for dofetilide in March. Dofetilide is a selective
channel blocker for the treatment of atrial fibrillation.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News